<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461733</url>
  </required_header>
  <id_info>
    <org_study_id>NA5936 Heart and Stroke</org_study_id>
    <secondary_id>OHREB Protocol # 2006430-01</secondary_id>
    <nct_id>NCT01461733</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit</brief_title>
  <acronym>AFIB</acronym>
  <official_title>Atrial Fibrillation WITHOUT Hemodynamic Stability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is an abnormal heart rhythm that is common among patients who are
      admitted to an intensive care unit (ICU) of a hospital. It is usually a transient occurrence
      that resolves as the patient recovers from their underlying condition. However, patients who
      develop AF can present with a very rapid heart rate that in some cases can put stress on the
      heart which can lead to life threatening heart attacks, low blood pressure or breathing
      problems. Not all patients with AF will have unstable heart function but those who have rapid
      heart rates can worsen quickly. The goals of treatment for AF with a rapid heart rate but no
      unstable heart function are two fold. Patients can be treated by controlling the heart rate
      and/or by attempting to convert the AF to a normal heart rhythm. The heart rate can be
      controlled by medication and the AF can be converted by either electrical cardioversion (an
      electric shock that jump-starts the heart) or medication. Currently it is unknown if the goal
      of treatment should be to simply control the heart rate and wait for the patient to
      spontaneously convert to a normal heart rhythm or convert the AF with medication for patients
      who only have the rapid heart rate.

      The objective of this project is to conduct a pilot study to determine if it would be
      feasible to conduct a larger definitive trial that would answer the following question:
      Should the goal of treatment be to control the rapid heart rate or resolve the abnormal heart
      rhythm in patients with AF who have a rapid heart rate without unstable heart function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion From Atrial Fibrillation to Sinus Rhythm</measure>
    <time_frame>From randomization to conversion or ICU discharge up to 100 months.</time_frame>
    <description>Conversion rates measured during ICU stay only. Average duration of ICU stay is 7 days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>amiodarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard dose amiodarone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amiodarone</intervention_name>
    <description>standard dose amiodarone</description>
    <arm_group_label>amiodarone</arm_group_label>
    <other_name>non applicable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo delivered blinded</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  new onset afib

        Exclusion Criteria:

          -  hemodynamically unstable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salmaan Kanji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <results_first_submitted>September 9, 2014</results_first_submitted>
  <results_first_submitted_qc>September 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>S. Kanji</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>amiodarone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amiodarone</title>
          <description>standard dose amiodarone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amiodarone</title>
          <description>standard dose amiodarone
amiodarone: standard dose amiodarone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: placebo delivered blinded</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="17"/>
                    <measurement group_id="B2" value="61" spread="17"/>
                    <measurement group_id="B3" value="65" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Conversion From Atrial Fibrillation to Sinus Rhythm</title>
        <description>Conversion rates measured during ICU stay only. Average duration of ICU stay is 7 days.</description>
        <time_frame>From randomization to conversion or ICU discharge up to 100 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone</title>
            <description>standard dose amiodarone
amiodarone: standard dose amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: placebo delivered blinded</description>
          </group>
        </group_list>
        <measure>
          <title>Conversion From Atrial Fibrillation to Sinus Rhythm</title>
          <description>Conversion rates measured during ICU stay only. Average duration of ICU stay is 7 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amiodarone</title>
          <description>standard dose amiodarone
amiodarone: standard dose amiodarone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: placebo delivered blinded</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Salmaan Kanji</name_or_title>
      <organization>The Ottawa Hospital Research Institute</organization>
      <phone>613-737-8899 ext 78159</phone>
      <email>skanji@toh.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

